… April 1 and is up only 6.6% YTD. Over the past five days alone the XBI ETF is up 3.5% while the SPY is down 1.42%. The FBT ($45.12) First Trust Arca Biotechnology Index Fund is up 38% YTD riding some big winners like Amylin ( AMLN ) Regeneron …
… Vertex's ( VRTX ) cystic fibrosis treatment - and because some investors are betting on deals occurring. One ETF that is doing particularly well this year is iShares Nasdaq Biotech ( IBB ). Others include XBI , FBT and BBH . Post your comment!
By Robert Hallberg : A lot of progress has been made in the field of biotechnology and biomedicine since the completion of the human genome projects in 2003. The completion of this project was a huge milestone, and it was supposed to usher in a new era of genetic medicine with new cures. But ...
By Tom Lydon : Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash and the
… First Trust NYSE Arca Biotechnology Index FBT (0.60%), iShares Nasdaq Biotechnology ..... Biotech ETF BBH (0.35%). Both XBI and FBT offer equal-weight exposure to the biotech ..... average market cap of $2.8 billion and FBT 's 20-stock portfolio has a holdings …
… the subsector is the smaller First Trust NYSE Arca Biotech Index FBT (0.60% expense ratio ..... concentrated, equal-weight index. FBT holds just 20 U.S.-listed ..... performance in recent years, FBT is the perfect example of a …
… First Trust NYSE Arca Biotechnology Index FBT (0.60%), PowerShares Dynamic Biotech ..... Biotech BBH (0.35%). Both XBI and FBT offer equal-weight exposure to the biotech ..... average market cap of $2.8 billion, and FBT 's 20-stock portfolio clocks in at an …
… Biotechnology IBB (0.48% expense ratio), First Trust NYSE Arca Biotech Index FBT (0.60%), Market Vectors Biotech ETF BBH ..... Biotechnology & Genome Portfolio PBE (0.63%). FBT , which holds 20 stocks, offers equal-weight …
By Helix Investment Management : Biotechnology is a sector that offers much in the way of both risk and reward. And for investors willing to research the sector, large profits are possible. We believe that Regeneron Pharmaceuticals ( REGN ) has the potential to offer investors profits, even after
… typically unrelated to another's. FBT rose a blistering 45% in 2009 ..... market cap of $3.3 billion. FBT tracks the NYSE Arca Biotechnology ..... each rebalancing. Suitability First Trust NYSE Arca Biotech Index FBT offers investors exposure to …